Crosstown Traffic: Lymphodepleting Chemotherapy Drives CAR T Cells
- PMID: 33417830
- DOI: 10.1016/j.ccell.2020.12.019
Crosstown Traffic: Lymphodepleting Chemotherapy Drives CAR T Cells
Abstract
CAR-engineered T cell immunotherapy has proven transformative in selected hematological malignancies. However, solid tumors largely remain impervious to these approaches. In addressing this challenge, Srivastava et al. in this issue demonstrate that oxaliplatin-based lymphodepleting chemotherapy promotes enhanced CAR T cell recruitment to lung tumors, boosting therapeutic impact in combination with anti-PD-L1.
Copyright © 2020 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests J.M. is CSO, scientific founder, and shareholder of Leucid Bio. D.M.D. is a consultant for Leucid Bio.
Comment on
-
Immunogenic Chemotherapy Enhances Recruitment of CAR-T Cells to Lung Tumors and Improves Antitumor Efficacy when Combined with Checkpoint Blockade.Cancer Cell. 2021 Feb 8;39(2):193-208.e10. doi: 10.1016/j.ccell.2020.11.005. Epub 2020 Dec 24. Cancer Cell. 2021. PMID: 33357452 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
